Overview

Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The primary objective: *To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group. Secondary Objective: - To measure the mean change in visual acuity from Baseline to Month 12. - To measure the mean change in central retinal thickness per OCT from Baseline to Month 12

Phase:

N/A

Details

Lead Sponsor:

Vision Research Foundation

Collaborator:

Genentech, Inc.

Treatments:

Ranibizumab